Chimeric Antigen Receptors for T-Cell Malignancies [PDF]
Frontiers in Oncology, 2019 Development of chimeric antigen receptor (CAR)-modified T cells for the treatment of T-lineage leukemia and lymphoma has encountered several unique challenges. The most widely expressed tumor antigen targets for malignant T cells are often also expressed
Lauren D. Scherer +8 more
doaj +4 more sources
T-cell antigen receptor genes and T-cell recognition [PDF]
Nature, 1988 The four distinct T-cell antigen receptor polypeptides (alpha, beta, gamma, delta) form two different heterodimers (alpha:beta and gamma:delta) that are very similar to immunoglobulins in primary sequence, gene organization and modes of rearrangement.
Mark M. Davis, P. Bjorkman
semanticscholar +5 more sources
Chimeric antigen receptors that trigger phagocytosis
eLife, 2018 Chimeric antigen receptors (CARs) are synthetic receptors that reprogram T cells to kill cancer. The success of CAR-T cell therapies highlights the promise of programmed immunity and suggests that applying CAR strategies to other immune cell lineages may
Meghan A Morrissey +6 more
doaj +2 more sources
Chimeric non-antigen receptors in T cell-based cancer therapy
Journal for ImmunoTherapy of Cancer, 2021 Adoptively transferred T cell-based cancer therapies have shown incredible promise in treatment of various cancers. So far therapeutic strategies using T cells have focused on manipulation of the antigen-recognition machinery itself, such as through ...
Andrew Kent, Eduardo Davila, Jitao Guo
doaj +1 more source
Therapeutic applications of engineered chimeric antigen receptors-T cell for cancer therapy
Beni-Suef University Journal of Basic and Applied Sciences, 2022 Background Findings of new targeted treatments with adequate safety evaluations are essential for better cancer cures and mortality rates. Immunotherapy holds promise for patients with relapsed disease, with the ability to elicit long-term remissions ...
Amina Hussain
doaj +1 more source
Mathematical Modeling Insights into Improving CAR T cell Therapy for Solid Tumors: Antigen Heterogeneity and Bystander Effects [PDF]
npj Systems Biology and Applications, 10(1), 105 (2024), 2023 As an adoptive cellular therapy, Chimeric Antigen Receptor T-cell (CAR T-cell) therapy has shown remarkable success in hematological malignancies, but only limited efficacy against solid tumors. Compared with blood cancers, solid tumors present a unique set of challenges that ultimately neutralize the function of CAR T-cells.
arxiv +1 more source
Toward high-throughput engineering techniques for improving CAR intracellular signaling domains
Frontiers in Bioengineering and Biotechnology, 2023 Chimeric antigen receptors (CAR) are generated by linking extracellular antigen recognition domains with one or more intracellular signaling domains derived from the T-cell receptor complex or various co-stimulatory receptors.
Savannah E. Butler +7 more
doaj +1 more source
Long-term outcomes following CAR T cell therapy: what we know so far
Nature Reviews Clinical Oncology, 2023 Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells to antigens expressed on cancer cells. CAR T cells are now an established treatment for patients with relapsed and/or refractory B cell lymphomas, B cell acute ...
Kathryn M. Cappell, J. Kochenderfer
semanticscholar +1 more source
Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. [PDF]
PLoS Pathogens, 2010 Exhausted CD8+ T cell responses during chronic viral infections are defined by a complex expression pattern of inhibitory receptors. However, very little information is currently available about the coexpression patterns of these receptors on human virus-
Bertram Bengsch +7 more
doaj +1 more source
A transfer-learning approach to predict antigen immunogenicity and T-cell receptor specificity
eLife, 2023 Antigen immunogenicity and the specificity of binding of T-cell receptors to antigens are key properties underlying effective immune responses. Here we propose diffRBM, an approach based on transfer learning and Restricted Boltzmann Machines, to build ...
Barbara Bravi +6 more
doaj +1 more source